title: Antibody-targeted chemotherapy of relapsed AML.
authors.forename: Philippe
authors.initials: P
authors.lastname: Mineur
authors.forename: Chantal
authors.initials: C
authors.lastname: Lejeune
authors.forename: Vincent
authors.initials: V
authors.lastname: Hennaux
authors.forename: Catharine
authors.initials: C
authors.lastname: Eten
mesh_terms: D000208:Acute Disease; D000368:Aged; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology; D000079982:Gemtuzumab; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007951:Leukemia, Myeloid / Q000276:immunology / Q000628:therapy*; D008297:Male; D012008:Recurrence; D063268:Sialic Acid Binding Ig-like Lectin 3; D016896:Treatment Outcome
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; C571163:CD33 protein, human; D063268:Sialic Acid Binding Ig-like Lectin 3; D000079982:Gemtuzumab